Squarepoint Ops LLC Geron Corp Transaction History

Squarepoint Ops LLC

$62.8 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.1 - $5.09 $950,695 - $1.56 Million	306,676 Added 559.54%	361,485 $1.53 Million
Q1 2024 May 15, 2024	SELL	$1.75 - $3.44 $590,429 - $1.16 Million	-337,388 Reduced 86.03%	54,809 $180,000
Q4 2023 Feb 14, 2024	BUY	$1.74 - $2.31 $290,266 - $385,354	166,820 Added 74.02%	392,197 $827,000
Q2 2023 Aug 14, 2023	BUY	$1.97 - $3.69 $443,992 - $831,641	225,377 New	225,377 $723,000
Q4 2022 Feb 14, 2023	SELL	$2.03 - $2.42 $75,087 - $89,513	-36,989 Reduced 63.12%	21,612 $52,000
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $97,863 - $172,286	58,601 New	58,601 $137,000
Q1 2022 May 16, 2022	SELL	$0.99 - $1.6 $75,016 - $121,238	-75,774 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.22 - $1.72 $5,927 - $8,357	4,859 Added 6.85%	75,774 $92,000
Q3 2021 Nov 15, 2021	SELL	$1.2 - $1.5 $61,690 - $77,113	-51,409 Reduced 42.03%	70,915 $97,000
Q2 2021 Aug 16, 2021	SELL	$1.25 - $1.83 $63,060 - $92,319	-50,448 Reduced 29.2%	122,324 $172,000
Q1 2021 May 17, 2021	BUY	$1.52 - $2.1 $262,613 - $362,821	172,772 New	172,772 $273,000
Q3 2020 Nov 16, 2020	SELL	$1.59 - $2.19 $17,994 - $24,784	-11,317 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.05 - $2.18 $11,882 - $24,671	11,317 New	11,317 $25,000
Q4 2019 Feb 14, 2020	SELL	$1.27 - $1.54 $106,786 - $129,489	-84,084 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$1.15 - $1.59 $35,822 - $49,528	31,150 Added 58.85%	84,084 $112,000
Q2 2019 Aug 14, 2019	BUY	$1.37 - $2.02 $72,519 - $106,926	52,934 New	52,934 $75,000
Q3 2018 Nov 14, 2018	SELL	$1.76 - $6.38 $171,536 - $621,820	-97,464 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$3.29 - $4.82 $320,656 - $469,776	97,464 New	97,464 $334,000

Others Institutions Holding GERN

# of Institutions

275

Shares Held

491M

Call Options Held

1.87M

Put Options Held

690K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.51B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.

Account